This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Renal osteodystrophy (affect of aluminium)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

In patients with chronic renal failure undergoing haemodialysis, aluminium toxicity may contribute to the observed skeletal changes. Aluminium accumulates in bone at the interface between mineralised bone and osteoid - the mineralisation front. It may suppress osteoblast activity and may accumulate in the parathyroid gland, where it can suppress PTH secretion.

The main sources of aluminium are the tap water used to prepare the dialysate solution and aluminium containing phosphate binding antacids used to treat uraemic secondary hyperparathyroidism. Fortunately, the reduction in the aluminium content of tap water has seen a reduction in this complication.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page